Welcome to Alitair Pharmaceuticals, Inc.

Alitair is a specialty pharmaceutical company with a focus on the respiratory space. Currently, we are developing two Orphan drugs for bronchiectasis. We expect to begin clinical trials for both compounds within the next 6 months.

We also have products under development for Rx and OTC cough treatment.  Our lead cough candidate is a solid oral dosage form of benzonatate which is protected by a composition of matter patent.

Alitair currently has four issued patents and we anticipate expanding our patent portfolio further in the near future.

This e-mail address is being protected from spambots. You need JavaScript enabled to view it for more information about our Orphan drug candidates and for our cough licensing opportunities.



Solution Managers